L 691831

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596652

CAS#: 136668-70-7

Description: L 691831 is a radioiodinated inhibitor of leukotriene synthesis.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-04-01. Prices are subject to change without notice.

L 691831 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 596652
Name: L 691831
CAS#: 136668-70-7
Chemical Formula: C36H38N2O4
Exact Mass: 562.2832
Molecular Weight: 562.71
Elemental Analysis: C, 76.84; H, 6.81; N, 4.98; O, 11.37

Synonym: L 691831; L-691831; L691831; L-691,831; L 691,831; L691,831;

IUPAC/Chemical Name: 3-(1-benzyl-3-(3,3-dimethylbutanoyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl)-2,2-dimethylpropanoic acid


InChi Code: InChI=1S/C36H38N2O4/c1-35(2,3)21-32(39)33-28-19-27(42-23-26-16-15-25-13-9-10-14-29(25)37-26)17-18-30(28)38(22-24-11-7-6-8-12-24)31(33)20-36(4,5)34(40)41/h6-19H,20-23H2,1-5H3,(H,40,41)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Macdonald D, Brideau C, Chan CC, Falgueyret JP, Frenette R, Guay J, Hutchinson JH, Perrier H, Prasit P, Riendeau D, Tagari P, Thérien M, Young RN, Girard Y. Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein. Bioorg Med Chem Lett. 2008 Mar 15;18(6):2023-7. doi: 10.1016/j.bmcl.2008.01.105. Epub 2008 Feb 2. PubMed PMID: 18276139.

2: Charleson S, Evans JF, Léger S, Perrier H, Prasit P, Wang Z, Vickers PJ. Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein. Eur J Pharmacol. 1994 May 17;267(3):275-80. PubMed PMID: 8088366.

3: Mancini JA, Coppolino MG, Klassen JH, Charleson S, Vickers PJ. The binding of leukotriene biosynthesis inhibitors to site-directed mutants of human 5-lipoxygenase-activating protein. Life Sci. 1994;54(9):PL137-42. PubMed PMID: 8114608.

4: Mancini JA, Abramovitz M, Cox ME, Wong E, Charleson S, Perrier H, Wang Z, Prasit P, Vickers PJ. 5-lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett. 1993 Mar 8;318(3):277-81. PubMed PMID: 8440384.

5: Charleson S, Prasit P, Léger S, Gillard JW, Vickers PJ, Mancini JA, Charleson P, Guay J, Ford-Hutchinson AW, Evans JF. Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition. Mol Pharmacol. 1992 May;41(5):873-9. PubMed PMID: 1588922.